Flomax

(Tamsulosin)

ApprovedSmall molecule

Tamsulosin is used to treat urinary symptoms of an enlarged prostate, such as difficulty urinating, weak urine stream, and needing to urinate frequently or urgently.[2] Flomax is currently approved and in use across 18 indications[4].[1]

Flomax is one of 349 small molecule programs targeting Hyperplasia. It is currently in Approved.

Indications

125

Total Trials

Active Trials

348

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

HyperplasiaActive, not recruiting

MydriasisActive, not recruiting

Erectile DysfunctionApproved

Chronic ProstatitisActive, not recruiting

Benign Prostatic HyperplasiaActive, not recruiting

Urinary RetentionApproved

Lower Urinary Tract SymptomApproved

UrolithiasisApproved

HysterectomyActive, not recruiting

UreterolithiasisApproved

HyperplasiaPhase 3

Active, not recruiting

MydriasisPhase 1

Active, not recruiting

Erectile DysfunctionApproved

Approved

Chronic ProstatitisPreclinical

Active, not recruiting

Benign Prostatic HyperplasiaApproved

Active, not recruiting

Urinary RetentionApproved

Approved

Lower Urinary Tract SymptomApproved

Approved

UrolithiasisApproved

Approved

HysterectomyPhase 2

Active, not recruiting

UreterolithiasisApproved

Approved

Showing 10 of 18 indications

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Flomax

Sanofi

Approved

1 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Jatenzo

GGrupo Espanol de Tumores Neuroendocrinos

Preclinical

2 5

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 6

Duragesic

CCephalon

Preclinical

1 7

Prednisone/prednisolone

Roche

Preclinical

3 8

Triptorelin Pamoate

Ipsen

Preclinical

2 9

Therapeutic Hydrocortisone

EEastern Cooperative Oncology Group

Preclinical

9 10

Ifex

BBaxter Healthcare Corporation

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Post-ApprovalNot yet recruiting

Randomized

NCT07467343

Phase 3Recruiting

Posterior Urethral Valve

NCT06737016

Phase 2Recruiting

Urinary Retention

NCT04597372

Phase 1Recruiting

Urinary Retention

NCT05657990

Phase 2Recruiting

Safety and Efficacy

NCT05401032

Post-ApprovalRecruiting

Benign Prostatic Hyperplasia

NCT05551221

Clinical

Trials by Indication[1]

Benign Prostatic Hyperplasia23 trials

Efficacy And Safety Of Combination Therapy For Treatment Of Overactive Bladder In Male Patients With Benign Prostatic Hyperplasia.

Unknown status·SSt. Joseph's Healthcare Hamilton·Phase 4·NCT02279615·200 enrolled

Pilot Study Investigating Safety and Efficacy of Tadalafil as Treatment for Benign Prostatic Hyperplasia (BPH) in Asian Men

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT00540124·151 enrolled

The Effect of Daily Tamsulosin 0.2mg Administration on Renal Function in Patients With Benign Prostatic Hyperplasia

Unknown status·TThe Catholic University of Korea·N/A·NCT02033798·34 enrolled

Show 20 more trials

Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02244320·4,150 enrolled

Multinational Study to Evaluate Tadalafil in Asian Men With Signs and Symptoms of Benign Prostatic Hyperplasia

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00861757·612 enrolled

Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 4·NCT02244229·403 enrolled

Comparison Between Tamsulosin and Tadalafil in Management of Benign Prostatic Hyperplasia Long Term Study

Completed·MMansoura University·Phase 4·NCT05818670·160 enrolled

Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia

Completed·SSiami, Paul F., M.D.·Phase 4·NCT00701779·63 enrolled

Efficacy and Safety of Longidaze in the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia

Completed·NNPO Petrovax·N/A·NCT06568718·229 enrolled

Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement

Completed· GSK logo

GSK·Phase 4·NCT01294592·742 enrolled

Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia

Completed·SSamsung Medical Center·Phase 4·NCT02034604·194 enrolled

Comparison of Finasteride and Tamsulosin for Treatment of Benign Prostatic Hyperplasia (BPH) (MK-0906A-149 AM2)

Terminated· Merck & Co. logo

Merck & Co.·Phase 3·NCT01534351·1 enrolled

Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia

Completed· GSK logo

GSK·Phase 3·NCT02058368·607 enrolled

Benign Prostatic Hyperplasia and Ischemic Heart DIsease

Completed·II.M. Sechenov First Moscow State Medical University·Phase 4·NCT03856242·83 enrolled

Clinical Trial To Evaluate the Efficacy and Safety of CKD-397 in Benign Prostatic Hyperplasia Patients

Completed· Chong Kun Dang Pharmaceutical logo

Chong Kun Dang Pharmaceutical·Phase 3·NCT03246880·455 enrolled

Effects of Tamsulosin 0.4mg on Clinical Outcomes in Korean Men With Severe Symptomatic Benign Prostatic Hyperplasia (BPH)

Unknown status·SSamsung Medical Center·N/A·NCT01404637·150 enrolled

The Efficacy and Safety of the Combination of Tamsulosin and Tadalafil in Men With Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia and Erectile Dysfunction

Unknown status· IlDong Pharmaceutical Co Ltd logo

IlDong Pharmaceutical Co Ltd·Phase 3·NCT02862483·330 enrolled

Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)

Completed·—·Phase 4·NCT04107896·141 enrolled

A Study of Tadalafil in Men With Benign Prostatic Hyperplasia

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00970632·511 enrolled

The Efficacy and Safety of Silodosin Singly or Combined With Ningmitai Capsules in the Treatment of Benign Prostatic Hyperplasia

Recruiting·XXintian Pharmaceutical·Phase 4·NCT05551221·312 enrolled

Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02245555·1,060 enrolled

Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02245529·982 enrolled

Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim··NCT02245503·7,391 enrolled

Urinary retention16 trials

Prophylactic Alpha-blockers in the Prevention of Urinary Retention Post Inguinal Hernia Repair

Unknown status·NNational University Hospital, Singapore·Phase 1·NCT03314259·300 enrolled

Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery

Recruiting·—·Phase 2·NCT04597372·154 enrolled

Tamsulosin vs Placebo to Prevent Postoperative Urinary Retention in Female Pelvic Reconstructive Surgery

Completed·UUniversity Hospitals Cleveland Medical Center·Phase 2/3·NCT03524339·132 enrolled

Show 13 more trials

Prophylactic Administration of Alpha Blockers for Prevention of Urinary Retention in Males Undergoing Inguinal Hernia Repair Under Spinal Anaesthesia.

Completed·GGeorgios Koukoulis·Phase 1/2·NCT03976934·100 enrolled

Prophylactic Tamsulosin Use for Prevention of Post-Operative Urinary Retention

Terminated·UUniversity of Rochester·N/A·NCT02684344·5 enrolled

Preoperative Administration of Tamsulosin for Prevention of Post Operative Urinary Retention in Males Undergoing Elective Inguinal Hernia Repair

Completed·AAscension Health·Phase 4·NCT02958878·210 enrolled

Prevention of Post-operative Urinary Retention

Completed·UUniversity of Wisconsin, Madison·Phase 3·NCT02486653·158 enrolled

Tamsulosin for Urinary Retention in Hospitalized Older Women

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT01747993·34 enrolled

Preoperative Tamsulosin to Prevent Postoperative Urinary Retention After Surgery For Pelvic Floor Disorders

Active, not recruiting·TThe Cleveland Clinic·Phase 1·NCT04232683·100 enrolled

Trial of Prophylactic Tamsulosin for Postoperative Urinary Retention in Primary Total Hip and Knee Arthroplasty Patients

Terminated·UUniversity of Michigan·Phase 3·NCT02518971·176 enrolled

Tamsulosin to Prevent Postoperative Urinary Retention in Laparoscopic Inguinal Hernia Repair

Terminated·—·Phase 4·NCT04434378·170 enrolled

Effect of Preoperative Tamsulosin on Postoperative Urinary Retention

Completed·EEndeavor Health·Phase 3·NCT05753670·179 enrolled

Post Operative Urinary Retention (POUR) Following Thoracic Oncological Surgery

Recruiting·HHackensack Meridian Health·Phase 1·NCT05657990·46 enrolled

The Effect of Tamsulosin on Postoperative Urinary Retention

Terminated·WWake Forest University Health Sciences·Phase 4·NCT04682366·4 enrolled

Prevention of Postoperative Urinary Retention With Treatment of Tamsulosin 5 Days Prior to Lower Limb Arthroplasty

Completed·KKantonsspital Graubünden·Phase 4·NCT03808155·170 enrolled

Hernia Surgery Urinary Retention

Unknown status·MMemorial Health University Medical Center·Phase 4·NCT03027115·140 enrolled

Treatment8 trials

Evaluation of Tamsulosin in the Treatment of Ureteral Stones

Completed·RRennes University Hospital·Phase 3·NCT00151567·129 enrolled

Trospium Chloride vs Tamsulosin in Treatment of Ureteral Stent Related Symptoms:

Suspended·MMansoura University·N/A·NCT03709992·200 enrolled

The Use of Tamsulosin in Treatment of (10-15 mm) Lower Ureteric Stones in Adults With Non-emergent Symptoms

Unknown status·—·Phase 1·NCT03274700·80 enrolled

Show 5 more trials

Comparison of Tamsulosin and Solifenacin in Treatment of Ureteral Stent Symptoms

Completed·MMansoura University·Phase 4·NCT01880619·131 enrolled

Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction

Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT01741454·181 enrolled

Behavior and Exercise Versus Drug Treatment in Men With Nocturia (BEDTiMe)

Completed·—·Phase 4·NCT00824200·72 enrolled

Silodosin Versus Tamsulosin for Treatment of Ureteral Stones

Terminated·AAlbert Einstein Healthcare Network·Phase 4·NCT02369744·1 enrolled

Efficacy of Mirabegron Versus Tamsulosin Versus Solifenacin for Treatment of Ureteral Stents-Related Symptoms

Unknown status·MMansoura University·Phase 3·NCT04325880·240 enrolled

Lower Urinary Tract Symptom5 trials

Study the Effects of Different Doses of UK-369,003 in Men With Lower Urinary Tract Symptoms.

Completed· Pfizer logo

Pfizer·Phase 2·NCT00457457·609 enrolled

Evaluation of Mirabegron Versus Tamsulosin or Their Combination in Treatment of Lower Urinary Tract Symptoms

Completed·AAvraiem Talaat·N/A·NCT07307261·300 enrolled

Efficacy and Safety of Tadalafil, Tamsulosin, and Their Combinations in Treating Lower Urinary Tract Symptoms in BPH Patients with Prostate Volumes ≤ 40 Ml: a Prospective Comparative Study

Completed·FFayoum University Hospital·Phase 4·NCT06809205·95 enrolled

Show 2 more trials

Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms

Completed· Astellas logo

Astellas·Phase 4·NCT02715024·52 enrolled

Pilot Trial Of Urinary Nerve Growth Factor (NGF) As Biomarker for Male Lower Urinary Tract Symptoms

Completed·—·Phase 4·NCT01457573·10 enrolled

MPA4 trials

Comparison of Mirabegron and Tamsulosin for Ureteral Stone Expulsion

Not yet recruiting·TTaipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation·Phase 4·NCT07310797·500 enrolled

COMPARISON OF SILODOSIN AND TAMSULOSIN IN MEDICAL EXPULSIVE THERAPY OF DISTAL URETERIC CALCULI

Completed·—·Phase 1·NCT05790902·142 enrolled

Effect of Tamsulosin on PE Compared With Paroxetine Hydrochloride

Unknown status·—·Phase 3·NCT03879746·160 enrolled

Show 1 more trial

Comparative Study Between Rezum and Tamsulosin

Completed·Kkhaled Abdelsattar Gad Ibrahim·N/A·NCT07169773·94 enrolled

49 more indications

Shock3 trials

Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy

Withdrawn·AAlbert Einstein Healthcare Network·Phase 3·NCT01560091

Can Acupoint Low Intensity Shockwave Therapy Improve Bladder Voiding Efficiency

Recruiting·—·N/A·NCT06020963·100 enrolled

Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ?

Unknown status·HHaEmek Medical Center, Israel··NCT00489723

TED3 trials

Comparing Patients After ESWL Treated With Ureteral Stents Versus Expulsion Therapy With Tamsulosin

Unknown status·HHadassah Medical Organization·Phase 2·NCT00478998

Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02417831·34 enrolled

Comparison of Alpha Blockers (Terazosin and Tamsulosin) in Reducing Ureteral Stent Related Symptoms

Recruiting·PPenang Hospital, Malaysia·Phase 3·NCT06966804·150 enrolled

Efficacy and Safety3 trials

Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS

Withdrawn·AApsen Farmaceutica S.A.·Phase 3·NCT01203371

Evaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPH

Completed·RRECORDATI GROUP·Phase 3·NCT00359905·1,228 enrolled

Efficacy and Safety of a Single TRUS-guided Intraprostatic Injection of NX-1207 in Patients With LUTS Due to BPH

Terminated·RRECORDATI GROUP·Phase 3·NCT02003742·104 enrolled

Renal Stones2 trials

Medical Expulsive Therapy Post-SWL For Renal Stones

Completed·MMansoura University·N/A·NCT05032287·235 enrolled

Tamsulosin as Adjunctive Therapy After Extracorporeal Shock Wave Lithotripsy for Renal Stones

Completed·HHospital Regional de Alta Especialidad del Bajio·Phase 4·NCT04819828·60 enrolled

Overactive Bladder2 trials

A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)

Completed· Astellas logo

Astellas·Phase 4·NCT02656173·568 enrolled

A Study to Evaluate Solifenacin Succinate in Combination With Tamsulosin for the Treatment of Residual Overactive Bladder Symptoms (OAB) in Men.

Completed· Astellas logo

Astellas·Phase 4·NCT00333112·398 enrolled

Fed2 trials

Tamsulosin Hydrochloride 0.4 mg Capsules Under Fed Conditions

Completed· Teva logo

Teva·Phase 1·NCT01149733·32 enrolled

Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02417844·34 enrolled

Prospective2 trials

Efficacy of Antihistamine Drugs as Medical Expulsive Therapy Alone or in Combination With Alpha Blockers: A Prospective Randomized Controlled Study

Completed·SSouth Valley University·Phase 3·NCT06754410·480 enrolled

Prospective Trial Comparing Oxybutynin and Tamsulosin for Stent Pain in the Pediatric Population

Withdrawn·PPhoenix Children's Hospital·N/A·NCT02483793

Urolithiasis2 trials

The Efficacy and Safety of Medical Expulsive Therapy After Extracorporeal Shock Wave Lithotripsy (ESWL) in Pediatric Urolithiasis

Unknown status·MMansoura University·N/A·NCT05759767·120 enrolled

Tamsulosin for Urolithiasis in the Emergency Dept

Completed·AAndrew Meltzer·Phase 4·NCT00382265·512 enrolled

AIN2 trials

Bioequivalence - Duodart Against Avodart & Omnic

Completed· GSK logo

GSK·Phase 1·NCT01657851·35 enrolled

Bioequivalence Study of Tamsulosin 0.4 mg Sustained Release Film-coated Tablets

Completed·DDexa Medica Group·Phase 1·NCT06558032·28 enrolled

Fasting Conditions2 trials

Tamsulosin Hydrochloride 0.4 mg Capsules Under Fasting Conditions

Completed· Teva logo

Teva·Phase 1·NCT01149746·32 enrolled

A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin Hydrochloride 0.4 mg, Prolonged-release Film-coated Tablets, in Healthy Adult Male Subjects, Under Fasting Conditions

Recruiting·BBerlin-Chemie AG Menarini Group·Phase 1·NCT07156916·46 enrolled

Emergency Department Patient2 trials

The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients

Completed·RRobert Swor·N/A·NCT00448123·127 enrolled

The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients

Completed·MMaineHealth·N/A·NCT00600405·81 enrolled

Monotherapy2 trials

Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients

Unknown status·SSeoul National University Hospital·Phase 4·NCT01736033·545 enrolled

Treatment of BPH With CO2 Serenoa +PEA as Monotherapy or in Combination With Tamsulosin: ProSeRePEA Trial

Unknown status·AAzienda Ospedaliero Universitaria Maggiore della Carita·N/A·NCT06181175·250 enrolled

Prolonged2 trials

A Comparative Bioavailability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tamsulosin 0.4 mg Tablets, in Healthy Adult Male Subjects, Under Fed Conditions

Active, not recruiting·BBerlin-Chemie AG Menarini Group·Phase 1·NCT07091669·46 enrolled

A Comparative Bioavalability Study of Tamsulosin 0.4 mg Prolonged-release Tablets Versus the Reference Drug Omnic Ocas®, Tabsulosine 0.4 mg Tablets in Healthy Adult Male Subjects, at Steady State

Active, not recruiting·BBerlin-Chemie AG Menarini Group·Phase 1·NCT07146711·33 enrolled

Hyperplasia2 trials

A Study to Evaluate the Efficacy and Safety of ASP4901 in Patients With Benign Prostate Hyperplasia

Completed· Astellas logo

Astellas·Phase 2·NCT02038868·320 enrolled

Efficacy and Safety of Tamsulosin/Solifenacin Combination Therapy in Patients With Voiding Symptoms and Moderate to Severe Storage Symptoms Due to Benign Prostate Hyperplasia

Unknown status· IlDong Pharmaceutical Co Ltd logo

IlDong Pharmaceutical Co Ltd·Phase 3·NCT02827578·588 enrolled

Chronic Prostatitis1 trial

Efficacy Study of Tamsulosin and Tolterodine Treatment for Chronic Prostatitis

Unknown status·—·N/A·NCT00913315·30 enrolled

ESS1 trial

Tamsulosin Assisted Ureteral Access Sheath Insertion

Unknown status·—·Phase 3·NCT05197088·110 enrolled

Prevention1 trial

Prevention of Acute Voiding Difficulty After Radical Proctectomy

Completed·SSeoul National University Hospital·Phase 3·NCT00606983·100 enrolled

Adverse Events1 trial

Tamsulosin and the Risk of Serious Adverse Events

Completed·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's··NCT07274228·14,000 enrolled

Function1 trial

Function of Tamsulosin in Older Males Undergoing Surgery with Indwelling Catheter

Recruiting·EEmory University·Phase 3·NCT06257576·212 enrolled

Posterior Urethral Valve1 trial

Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve.

Recruiting·MMansoura University·Phase 3·NCT06737016·50 enrolled

Drug1 trial

A Study to Compare the Amount of Drug in the Blood After a Single Tablet EC905 Containing Solifenacin and Tamsulosin is Taken by Healthy Males Compared to Separate Tablets of Solifenacin and Tamsulosin

Completed· Astellas logo

Astellas·Phase 1·NCT01953887·30 enrolled

Refractory1 trial

Clinical Effect and Safety of Tamsulosin 0.4mg in Patients With LUTS/BPH Refractory to Tamsulosin 0.2mg

Unknown status·SSamsung Medical Center·N/A·NCT00954889·220 enrolled

Hysterectomy1 trial

Pre-operative Tamsulosin and Time to Spontaneous Void After Hysterectomy

Completed·UUniversity of Arizona·Phase 2·NCT04859660·161 enrolled

Multiple Sclerosis1 trial

Efficacy of Alpha-blockers (Tamsulosin) in the Treatment of Symptomatic Dysuria in Multiple Sclerosis in Women

Recruiting·—·N/A·NCT05439902·60 enrolled

Interaction1 trial

Evaluating a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin

Completed· Hanmi Pharmaceutical Company Limited logo

Hanmi Pharmaceutical Company Limited·Phase 1·NCT02239484·30 enrolled

Medication1 trial

Medication Effects on Periurethral Sensation,Urethral Sphincter Activity and Pressure Flow Parameters

Completed·UUniversity of Alabama at Birmingham·N/A·NCT01028014·56 enrolled

Spine Surgery1 trial

Decreasing Rates of Intraurethral Catheterization Postoperatively in Spine Surgery

Completed·—·Phase 4·NCT02919436·610 enrolled

Clinical Trial1 trial

Clinical Trial to Investigate the Pharmacokinetic Drug Interaction Between Solifenacin and Tamsulosin

Completed· Jeil Pharmaceutical Co., Ltd. logo

Jeil Pharmaceutical Co., Ltd.·Phase 1·NCT02180997·36 enrolled

Irritation1 trial

Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation

Terminated·UUniversity of Kansas Medical Center·Phase 4·NCT03750656·5 enrolled

Trial1 trial

Ureteral Stent-related Pain and Mirabegron (SPAM) Trial

Completed·NNova Scotia Health Authority·Phase 4·NCT02095665·22 enrolled

Cardiovascular1 trial

A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin

Completed· Astellas logo

Astellas·Phase 1·NCT01489696·48 enrolled

Prostate Cancer1 trial

A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer

Active, not recruiting·—·Phase 2·NCT04147806·30 enrolled

Efficacy1 trial

The Efficacy of Alpha-blockers for Expulsion of Distal Ureteral Stones

Unknown status·SSoroka University Medical Center·Phase 4·NCT00451061·120 enrolled

Bladder Cancer1 trial

Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression

Unknown status·—·Phase 4·NCT02443844·40 enrolled

Safety and Efficacy1 trial

Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients with BPH.

Recruiting·—·Phase 2·NCT05401032·70 enrolled

Extracorporeal Shockwave Lithotripsy1 trial

Effects of the Use of Adjuvant Drugs After Extracorporeal Shockwave Lithotripsy (ESWL) in Renal Calculus

Unknown status·UUniversity of Sao Paulo General Hospital·Phase 3·NCT01215708·136 enrolled

Prostatectomy1 trial

Impact of Tamsulosin on Voiding Patterns Following Early Catheter Removal After Robot-assisted Laparoscopic Radical Prostatectomy

Unknown status·—·N/A·NCT01209988·220 enrolled

Randomized Controlled Trial1 trial

Effect of Perioperative Selective alpha1-blockers in Non-stented Ureteroscopic Laser Lithotripsy for Ureteric Stones: A Randomized Controlled Trial

Completed·—·Phase 3·NCT04557202·120 enrolled

DME1 trial

Evaluation of Bromocriptine, Metoprolol and Tamsulosin in Eyes With Non-Central DME

Withdrawn·UUnknown Sponsor·Phase 1/2·NCT03384524

Voiding Dysfunction1 trial

Perioperative Tamsulosin for Treating Voiding Dysfunction Following Prostate Biopsy

Not yet recruiting·PPeking University First Hospital·Phase 4·NCT07276919·1,844 enrolled

BPH1 trial

Intermittent vs Daily Tamsulosin for LUTS/BPH

Not yet recruiting·MMansoura University·Phase 4·NCT07308002·288 enrolled

Acute1 trial

Medical Stone Expulsive Therapy for Acutely Obstructed Ureteric Calculi

Completed·GGetz Pharma·Phase 4·NCT05977647·240 enrolled

Tics1 trial

Study to Investigate the Effect of Paroxetine Mediated CYP2D6 Inhibition on the Pharmacokinetics of Tamsulosin in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02264184·24 enrolled

Thyroid1 trial

Tamsulosin for Thyroid Lid Retraction

Unknown status·SSheba Medical Center·N/A·NCT04359979·50 enrolled

Randomized1 trial

Silodosin vs Tamsulosin for LUTS Due to BPH: A Randomized Crossover Trial

Not yet recruiting·—·Phase 4·NCT07467343·140 enrolled

Surgery1 trial

Peri-operative Tamsulosin and Impact on Voiding Trial After Same-day Urogynecology Surgery

Recruiting·TTriHealth Inc.·Phase 3·NCT06843538·166 enrolled

Double J Stent1 trial

Comparing Tamsulosin and Solifenacin for Relieving Double J Stent Symptoms: Using the USSQ.

Completed·LLiaquat National Hospital & Medical College·Phase 4·NCT07114848·60 enrolled

Mydriasis1 trial

Study to Assess the Influence of Three Different α-antagonists and Placebo on the Extent of Weekly Phenylephrine-induced Mydriasis at Three Different Concentrations of Phenylephrine in Healthy Male Volunteers

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 1·NCT02266537·97 enrolled

Unspecified4 trials

Medical Expulsive Therapy of Single Distal Ureteral Stones

Completed·UUniversity of Zurich·N/A·NCT00831701·100 enrolled

Silodosin vs Tamsulosin as MET

Unknown status·—·Phase 3·NCT05570084·80 enrolled

An 8-week, Open-label, Uncontrolled Study of Tamsulosin 0.4mg in Men With Bothersome Urinary Symptoms

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01726270·689 enrolled

Show 1 more trial

Deprescribing Tamsulosin in Older Men

Completed·UUniversity of California, San Francisco·Phase 4·NCT05415748·31 enrolled

Regulatory

FDA Approval Timeline[5]

Apr 15, 1997

FLOMAX

NDA NDA020579

Sources

References

[1]
ClinicalTrials.gov — 125 trial records for Tamsulosin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Flomax drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Tamsulosin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Tamsulosin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020579). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Adrenergic Receptor Alpha-1 Antagonist[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Sanofi

Flomax

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Benign Prostatic Hyperplasia23 trials

Urinary retention16 trials

Treatment8 trials

Lower Urinary Tract Symptom5 trials

MPA4 trials

Shock3 trials

TED3 trials

Efficacy and Safety3 trials

Renal Stones2 trials

Overactive Bladder2 trials

Fed2 trials

Prospective2 trials

Urolithiasis2 trials

AIN2 trials

Fasting Conditions2 trials

Emergency Department Patient2 trials

Monotherapy2 trials

Prolonged2 trials

Hyperplasia2 trials

Chronic Prostatitis1 trial

ESS1 trial

Prevention1 trial

Adverse Events1 trial

Function1 trial

Posterior Urethral Valve1 trial

Drug1 trial

Refractory1 trial

Hysterectomy1 trial

Multiple Sclerosis1 trial

Interaction1 trial

Medication1 trial

Spine Surgery1 trial

Clinical Trial1 trial

Irritation1 trial

Trial1 trial

Cardiovascular1 trial

Prostate Cancer1 trial

Efficacy1 trial

Bladder Cancer1 trial

Safety and Efficacy1 trial

Extracorporeal Shockwave Lithotripsy1 trial

Prostatectomy1 trial

Randomized Controlled Trial1 trial

DME1 trial

Voiding Dysfunction1 trial

BPH1 trial

Acute1 trial

Tics1 trial

Thyroid1 trial

Randomized1 trial

Surgery1 trial

Double J Stent1 trial

Mydriasis1 trial

Unspecified4 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News